Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants.

Zhang M, Ge G, Yang Y, Cai X, Fu Q, Cai J, Huang Z.

Virol J. 2013 Sep 22;10:292. doi: 10.1186/1743-422X-10-292.

2.

Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant.

Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS.

Antivir Ther. 2008;13(3):439-47.

PMID:
18572757
3.

Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil.

Mantovani N, Cicero M, Santana LC, Silveira C, do Carmo EP, Abrão PR, Diaz RS, Caseiro MM, Komninakis SV.

Virol J. 2013 Oct 28;10:320. doi: 10.1186/1743-422X-10-320.

4.
5.

High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.

Neumann-Fraune M, Beggel B, Pfister H, Kaiser R, Verheyen J.

J Med Virol. 2013 May;85(5):775-9. doi: 10.1002/jmv.23530.

PMID:
23408582
6.
8.

Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy.

Lin CL, Chien RN, Hu CC, Lai MW, Yeh CT.

J Antimicrob Chemother. 2012 Jan;67(1):39-48. doi: 10.1093/jac/dkr416.

PMID:
22001270
9.

Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B.

Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E.

J Infect. 2013 Oct;67(4):322-8. doi: 10.1016/j.jinf.2013.06.006.

PMID:
23796869
10.

Antiviral resistance mutations potentiate HBV surface antigen-induced transcription of hfgl2 prothrombinase gene.

Li W, Han M, Li Y, Chen D, Luo X, Ning Q.

Biochemistry (Mosc). 2011 Sep;76(9):1043-50. doi: 10.1134/S0006297911090094.

PMID:
22082274
11.

Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.

Luo Q, Zhong Y, Yang Y, Xiong Q, Hu Z, Lu W, Huang P, Zhang N.

J Med Virol. 2012 Oct;84(10):1558-61. doi: 10.1002/jmv.23369.

PMID:
22930503
12.

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.

Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC.

Virology. 2002 Feb 15;293(2):305-13.

13.

Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.

Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F.

J Virol. 2010 Jan;84(2):1026-33. doi: 10.1128/JVI.01796-09.

14.

Hepatitis B escape mutants in Scottish blood donors.

Larralde O, Dow B, Jarvis L, Davidson F, Petrik J.

Med Microbiol Immunol. 2013 Jun;202(3):207-14. doi: 10.1007/s00430-012-0283-9.

PMID:
23274404
15.

Construction and expression of hepatitis B surface antigen escape variants within the "a" determinant by site directed mutagenesis.

Golsaz Shirazi F, Amiri MM, Mohammadi H, Bayat AA, Roohi A, Khoshnoodi J, Zarnani AH, Jeddi-Tehrani M, Kardar GA, Shokri F.

Iran J Immunol. 2013 Sep;10(3):127-38. doi: IJIv10i3A1.

PMID:
24076590
16.

Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.

Kamili S, Sozzi V, Thompson G, Campbell K, Walker CM, Locarnini S, Krawczynski K.

Hepatology. 2009 May;49(5):1483-91. doi: 10.1002/hep.22796.

PMID:
19274751
17.
18.

Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.

Xu WZ, Fang Y, Li D, Wang Y, Shang QL, Li GQ, Teng X, Gu HX.

World J Gastroenterol. 2008 Jun 21;14(23):3733-8.

19.

The genetic backbone modulates the phenotype of hepatitis B surface antigen mutants.

Beale MA, Ijaz S, Tedder RS.

J Gen Virol. 2010 Jan;91(Pt 1):68-73. doi: 10.1099/vir.0.013078-0.

PMID:
19759242
20.

Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.

Sayan M, Akhan SC.

Int J Infect Dis. 2011 Oct;15(10):e722-6. doi: 10.1016/j.ijid.2011.05.019.

Items per page

Supplemental Content

Support Center